Scarica l'app Stockscreener
2.67
2.30%
0.06
Dopo l'orario di chiusura:
2.66
-0.010
-0.37%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EDIT Giù?
Forum
Previsione
Precedente Chiudi:
$2.61
Aprire:
$2.57
Volume 24 ore:
1.12M
Relative Volume:
0.63
Capitalizzazione di mercato:
$261.32M
Reddito:
$40.52M
Utile/perdita netta:
$-160.06M
Rapporto P/E:
-1.4176
EPS:
-1.8834
Flusso di cassa netto:
$-165.85M
1 W Prestazione:
+15.09%
1M Prestazione:
+24.19%
6M Prestazione:
-31.36%
1 anno Prestazione:
+126.27%
Intervallo 1D:
$2.53
$2.69
Intervallo di 1 settimana:
$2.13
$2.75
Portata 52W:
$0.9101
$4.5372
Editas Medicine Inc Stock (EDIT) Company Profile
Nome
Editas Medicine Inc
Settore
Industria
Telefono
617-401-9000
Indirizzo
11 HURLEY ST., CAMBRIDGE, MA
Compare EDIT vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
2.67 | 261.32M | 40.52M | -160.06M | -165.85M | -1.8834 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-28 | Iniziato | H.C. Wainwright | Buy |
| 2024-12-16 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-12-13 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2024-12-13 | Downgrade | Stifel | Buy → Hold |
| 2024-12-13 | Downgrade | Truist | Buy → Hold |
| 2024-12-11 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Downgrade | BofA Securities | Buy → Underperform |
| 2024-11-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-11-04 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2024-08-08 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-05-09 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-24 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-10-18 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-10-17 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-29 | Aggiornamento | Stifel | Hold → Buy |
| 2023-06-12 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-02-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-12-13 | Iniziato | Citigroup | Neutral |
| 2022-12-06 | Ripresa | Credit Suisse | Neutral |
| 2022-11-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-11-18 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-09-29 | Iniziato | BofA Securities | Neutral |
| 2021-10-19 | Iniziato | SVB Leerink | Mkt Perform |
| 2021-09-24 | Iniziato | Stifel | Hold |
| 2021-09-10 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-08-09 | Aggiornamento | Truist | Hold → Buy |
| 2021-08-05 | Aggiornamento | Evercore ISI | Underperform → Outperform |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-05-04 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2021-04-16 | Iniziato | Goldman | Sell |
| 2021-03-22 | Iniziato | Credit Suisse | Outperform |
| 2021-03-01 | Downgrade | Barclays | Overweight → Equal Weight |
| 2021-02-26 | Downgrade | Truist | Buy → Hold |
| 2021-01-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-01-07 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-12-10 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-11-03 | Iniziato | Robert W. Baird | Underperform |
| 2020-06-18 | Ripresa | SunTrust | Buy |
| 2020-02-21 | Iniziato | Wells Fargo | Equal Weight |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2018-10-10 | Iniziato | Guggenheim | Neutral |
| 2018-09-21 | Iniziato | Raymond James | Outperform |
| 2018-05-15 | Reiterato | Chardan Capital Markets | Buy |
| 2018-02-13 | Iniziato | CLSA | Underperform |
| 2018-01-23 | Aggiornamento | SunTrust | Hold → Buy |
| 2017-07-14 | Iniziato | SunTrust | Hold |
| 2017-03-28 | Iniziato | Chardan Capital Markets | Buy |
| 2016-08-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2016-06-02 | Iniziato | Jefferies | Hold |
| 2016-02-29 | Iniziato | JMP Securities | Mkt Outperform |
| 2016-02-29 | Iniziato | JP Morgan | Neutral |
| 2016-02-29 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Editas Medicine Inc Borsa (EDIT) Ultime notizie
Price Action: Will Editas Medicine Inc benefit from sector rotation2026 Trade Ideas & Weekly High Conviction Ideas - baoquankhu1.vn
Editas Medicine shares edge higher after Q4 earnings and revenue top estimates - MSN
EDIT Should I Buy - Intellectia AI
Gene Editing Market Set to Boom Rapidly by 2033 |CRISPR - openPR.com
Volume Report: Can Editas Medicine Inc ride the EV waveGold Moves & Low Risk Entry Point Guides - baoquankhu1.vn
Editas Medicine Inc Stock: Genome Editing Pioneer Faces Key Milestones in Competitive Biotech Landsc - AD HOC NEWS
Fundamentals Check: Will Editas Medicine Inc benefit from sector rotationGap Up & Risk Managed Investment Signals - baoquankhu1.vn
Setup Watch: Does Editas Medicine Inc have strong fundamentals2026 Top Gainers & Expert-Curated Trade Recommendations - baoquankhu1.vn
Editas Medicine Inc. (EDIT) Confirms EDT-401 as Lead Vivo Program - MSN
EDIT PE Ratio & Valuation, Is EDIT Overvalued - Intellectia AI
Editas Medicine Inc Stock: Gene Editing Pioneer Faces Clinical and Market Hurdles in Biotechnology L - AD HOC NEWS
Editas Medicine wins CRISPR patent ruling from USPTO - StreetInsider
USPTO Ruling Impacts Editas Medicine CRISPR IP Position - TipRanks
Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference - Bitget
USPTO Reaffirms Broad Institute’s Patents in CRISPR/Cas9 Dispute - geneonline.com
CRISPR patent win bolsters Editas Medicine (NASDAQ: EDIT) IP estate - Stock Titan
[SCHEDULE 13G/A] Editas Medicine, Inc. Amended Passive Investment Disclosure - Stock Titan
EDITAS MEDICINE Operating Margin %: -56.65% | Fairly Valued - GuruFocus
MACD Signal: Can Editas Medicine Inc maintain sales growthEarnings Summary Report & Community Consensus Stock Picks - baoquankhu1.vn
How correlated is Editas Medicine Inc to the S P5002026 Pullback Review & High Yield Equity Trading Tips - baoquankhu1.vn
Q2 EPS Estimates for Editas Medicine Decreased by Analyst - MarketBeat
Zacks Research Weighs in on Editas Medicine FY2028 Earnings - MarketBeat
If You Invested $1,000 in Editas Medicine Inc (EDIT) - Stock Titan
Editas Medicine, Inc. Trade Ideas — LS:A2AC4K - TradingView
RSI Check: Can Editas Medicine Inc outperform in the next rally2026 EndofMonth & High Accuracy Investment Signals - baoquankhu1.vn
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX), DocGo (DCGO) and Editas Medicine (EDIT) - The Globe and Mail
Institution Moves: Can Editas Medicine Inc disrupt its industry2026 News Drivers & Technical Pattern Based Buy Signals - baoquankhu1.vn
Editas Medicine (EDIT) Stock: 5-Year Valuation Drop & Recent Pipeline ChallengesNews and Statistics - IndexBox
Is Editas Medicine Going to $0? - The Globe and Mail
Can Editas Medicine Inc grow without external funding2026 Macro Impact & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Editas Medicine (EDIT) and Ascend Wellness Holdings LLC (OtherAAWH) - The Globe and Mail
Is Editas Medicine Headed Toward Zero? - Bitget
Editas Medicine (EDIT) grants 292,856 stock options to chief scientific officer - Stock Titan
Editas Medicine (EDIT) CEO awarded 1.02M stock options vesting over 4 years - Stock Titan
Editas Medicine Details In Vivo CRISPR Plan, Targets Year-End Human Proof-of-Concept for EDIT-401 - MarketBeat
Editas Medicine at Barclays Conference: Strategic Focus on CRISPR Innovation - Investing.com Canada
Regulatory Disruptions at FDA Threaten Editas Medicine’s Gene-Editing Timelines and Commercial Prospects - TipRanks
Editas Medicine (EDIT) Receives Upgrade to 'Buy' from Jones Trad - GuruFocus
Editas Medicine (NASDAQ:EDIT) Upgraded at JonesTrading - MarketBeat
EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y - The Globe and Mail
Jones Trading upgrades Editas Medicine stock rating on gene therapy progress - Investing.com Canada
Editas Medicine 2025 Annual Report: CRISPR Gene Editing Pipeline, EDIT-401 Program, Intellectual Property, and Industry Competition - Minichart
Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates - Bitget
Editas: Q4 Earnings Snapshot - theheraldreview.com
Cowen Maintains Buy on EDIT Editas Medicine, Inc. March 2026 - Meyka
Baird reiterates Editas Medicine stock rating on pipeline progress By Investing.com - Investing.com Canada
Editas Medicine 10-K: $40.5M revenue, $(1.80) EPS - TradingView
Editas Medicine (NASDAQ: EDIT) pivots to in vivo CRISPR and monetizes IP - Stock Titan
Editas Medicine (EDIT): Today's Analyst Rating Insights | EDIT S - gurufocus.com
Editas Medicine (NASDAQ:EDIT) Receives "Buy" Rating from Chardan Capital - MarketBeat
Editas Medicine Inc Azioni (EDIT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):